Summary. Advances in the management of patients with suspected pulmonary embolism (PE) have improved diagnostic accuracy and made management algorithms safer, easier to use, and well standardized. These diagnostic algorithms are mainly based on the assessment of clinical pretest probability, D-dimer measurement, and imaging tests-predominantly computed tomography pulmonary angiography. These diagnostic algorithms allow safe and cost-effective diagnosis for most patients with suspected PE. In this review, we summarize signs and symptoms of PE, current existing evidence for PE diagnosis, and focus on the challenge of diagnosing PE in special patient populations, such as pregnant women, or patients with a prior VTE. We also discuss novel imaging tests for PE diagnosis and highlight some of the additional challenges that might require adjustments to current diagnostic strategies, such as the reduced clinical suspicion threshold, resulting in a lower proportion of PE among suspected patients as well as the overdiagnosis of subsegmental PE.
Introduction
Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease after acute coronary syndrome and stroke. Due to its nonspecific clinical presentation, the diagnosis of PE remains difficult. One of the main challenges in everyday clinical practise is determining when to suspect PE. There remains a gap between management outcome studies and real life. For example, in most clinical trials studying diagnostic strategies for PE, patients were included if they had acute or worsening shortness of breath and/or chest pain without any obvious explanation. In real life, this definition of 'suspected PE' does not sufficiently help clinicians determine whether they should suspect PE in their patient.
The ever-increasing availability of non-invasive imaging tests, mainly computed tomography pulmonary angiography (CTPA), has led to a tendency to suspect PE much more frequently in outpatients than before, with a shift toward aiming to exclude PE in any patient presenting with chest symptoms rather than to confirm PE in a patient with high suspicion. This overall tendency is well illustrated by the decreasing incidence of PE in clinical studies, that is the decreasing percentage of patients among all suspected patients in whom the diagnosis of PE is confirmed. Incidences as low as 5% have been reported in some recent North American studies, a figure that contrasts with the~50% incidence reported in the early 1980s [1] .
This major change in the population of patients tested for suspected PE in clinical practise explains why current diagnostic management studies are designed to assess how to exclude PE in a population of patients with a rather low incidence of the disease. This is nowadays performed through the use of a test with high sensitivity, namely D-dimer measurement, at the beginning of the diagnostic management, before imaging. The gold standard reference for the diagnosis of PE remains pulmonary angiography, although the invasiveness, costs, and risks of this test have rendered it obsolete in routine clinical practise.
In light of these elements, the performance of modern diagnostic strategies for PE is most often presented as their ability to safely exclude PE. Because the gold standard test is no longer performed, the reference standard to confirm the safety of any strategy has nowadays become a clinical standard: an uneventful follow-up in patients left without anticoagulant treatment after a 'negative' strategy, expressed as a low three-month VTE rate. As the three-month VTE rate after a normal pulmonary angiography is known to be~2%, it is now well accepted that modern diagnostic strategies should be associated with a similar three-month thromboembolic risk in a patient considered as not having PE based on a negative strategy.
Tremendous advances have been made in the field of PE diagnosis over the last 30 years with the introduction of sequential diagnostic strategies including clinical probability assessment and D-dimer measurement, allowing ruling out PE in one of three outpatients in a completely non-invasive and cost-effective way. The remaining twothirds of patients require imaging tests, and CTPA is at present the imaging modality of choice. Unfortunately, the widespread use of multidetector CTPA without selecting patients has introduced new issues, such as overdiagnosis and radiation [2, 3] . An effort to implement the robust validated strategies in clinical practise could overcome some of these problems.
Finally, two conflicting issues confront clinicians faced with suspected VTE: not missing a VTE because of the risk of death in untreated patients, and not unnecessarily treating patients because of the bleeding risk of anticoagulants. Therefore, all patients with suspected VTE should be investigated until a definitive diagnosis is reached. Not meeting this goal exposes patients to a significantly higher risk of recurrent VTE and death. In this review, we will discuss the challenges of diagnosing PE, recent major improvements made in diagnostic strategies, as well as some unresolved issues.
Clinical presentation

Clinical syndromes
Symptoms of PE are neither very sensitive nor specific. In other words, the presence or absence of any single symptom or clinical sign is never sufficient to rule in or out the diagnosis. In 65% of patients, PE is suspected because of pleuritic chest pain, accompanied or not by dyspnea. Isolated dyspnea, usually acute but sometimes slowly progressive and without an obvious alternative cause, points toward PE in 20% of patients [4] . Syncope and shock are rare clinical presentations of PE (less than 10%). However, a recent study suggested that PE was identified in nearly one of every six patients hospitalized for a first episode of syncope [5] . Lastly, PE may be discovered in the absence of a clinical suspicion (so-called incidental PE), notably on CT scans performed for other indications, such as cancer staging. Symptomatic PE may present as three distinct syndromes of different pathology and variable severity [6] .
Alveolar hemorrhage
The clinical hallmark of this syndrome is pleuritic pain due to irritation of the visceral pleura and more rarely hemoptysis. Alveolar hemorrhage is due to peripheral emboli. Although alveolar hemorrhage is often incorrectly referred to as 'pulmonary infarction', the histopathological correlate is in fact an alveolar hemorrhage probably provoked by the influx of blood from the high-pressure bronchial circulation in the segment obstructed by the embolus [7] . The classical radiological picture is a wedge-shaped pleural-based infiltrate that affects approximately 20% of patients [8] . Other common chest X-ray anomalies include plate-like atelectasis and pleural effusion. Tachycardia and dyspnea are less frequent in this clinical syndrome, reflecting the peripheral character and lesser hemodynamic repercussions of such pulmonary emboli [6] .
Isolated dyspnea The absence of systematic pleuritic pain in this syndrome is likely due to a more proximal embolization level in the pulmonary vasculature. Patients may complain of oppressive retrosternal chest pain suggesting the differential diagnosis of angina pectoris. In fact, such pain probably reflects true myocardial ischemia due to increased right ventricular wall tension and reduced right coronary artery flow. Tachycardia is present in only 45% of patients [6] . Electrocardiogram is rarely normal, but abnormalities are often non-specific. Although dyspnea is usually of abrupt or rapid onset, in some patients it may progress over several days or even weeks.
Syncope or shock Syncope and/or shock are the clinical manifestations of high-risk (formerly massive) PE [9] causing acute severe pulmonary hypertension and right ventricular failure. It is usually due to large central clots. Although suggestive of PE in patients with obvious risk factors such as recent surgery, syncope may be a misleading presentation [5, 10] . Suspected massive PE with shock is a distinct situation requiring a specific diagnostic approach.
Because all these signs and symptoms are not specific and are also encountered in many potentially fatal cardio-pulmonary conditions, many patients undergo testing to exclude PE.
The challenge of suspecting PE
Over the last two decades, there has been a trend toward testing more patients for PE, resulting in a decrease in the proportion of confirmed cases. Indeed, in some recent studies, as few as 5% of patients with suspected PE are actually diagnosed with this condition [1] . This raises the question of when and in whom, a clinician should suspect PE. In most studies on PE diagnosis, patients were included if they presented with sudden onset or worsening of dyspnea or chest pain without another obvious cause [11, 12] . This definition is admittedly difficult to standardize, and there is probably a trade-off between oversuspecting and overtesting for PE versus missing PE diagnosis. Searching for PE in all patients with dyspnea or chest pain likely would lead to increases in cost and test complications without improvements in health.
Therefore, a new challenge is to better select who should be suspected of having PE. A clinical prediction rule (the PERC rule) was built in emergency department patients to identify those at such low risk of PE on clinical grounds that they would not need any other investigation [13] . Overall incidence of PE was 11% in their derivation set. The final model comprised of eight variables significantly associated with absence of PE: age < 50 years, pulse < 100 bpm, SaO2 > 94%, no unilateral leg swelling, no hemoptysis, no recent trauma or surgery, no history of VTE, no estrogen use. If all these criteria are absent, then PE should not be further investigated. In a validation set of 1427 patients with an incidence of PE of 8%, the rule was negative (all criteria met) in 25%. Among these, PE was found in only 1.4% (5/362, 95% CI 0.4 to 3.2) suggesting that such patients would not need to be tested for PE. The same figure was obtained in a prospective validation study of 8138 emergency room patients in the United States who were included if the physician in charge ordered any objective diagnostic test for PE. Twenty-four percent of those patients were classified into the low-risk group, and 1.3% of them had PE at the initial workup or during the 45-day follow-up [14] . However, attempts of retrospective validation of this rule in European cohorts of patients (with a higher incidence of the disease) suggested that the rule could not be used safely in populations of patients different from the initial studies as it was associated with a higher three-month thromboembolic risk of 6.7% (95% CI: 3-14) [15] in patients with a negative PERC rule. Further ongoing studies aim at prospectively validating the rule alone or in combination with a low pretest clinical probability (NCT02360540).
Overview of current diagnostic strategies
Confirmatory imaging tests such as CTPA or V/Q scan are associated with a non-negligible radiation dose and are also expensive. Given the low incidence of confirmed PE among tested patients, systematic imaging is not costeffective and is likely harmful. Therefore, current diagnostic strategies aim at identifying a group of low-risk patients, among patients with suspected PE, in whom no imaging test is required.
Clinical probability of pulmonary embolism
As previously discussed, sensitivity and specificity of clinical symptoms and signs are low when considered in isolation in patients with suspected PE. Nevertheless, these findings can be combined, either implicitly [16, 17] or by prediction rules [18, 19] , in order to estimate the likelihood of a patient with suspected PE to actually have confirmed PE. Both means of assessing clinical likelihood of PE allow a fairly accurate stratification of patients into two (PE unlikely or PE likely) or three (low, intermediate or high clinical probability) categories corresponding to an increasing incidence of PE [11, 12] . The two most widely used prediction rules for PE are the Wells rule and the Geneva rule. Two meta-analyses confirmed the validity of the original and simplified versions of the Wells and the revised Geneva rules [20, 21] . A direct prospective comparison of these rules has also confirmed similar diagnostic performances [22] . Of note, these rules should not be used as 'PE suspicion rules' applied as a screening test to all patients with chest symptoms in the ER, but rather should only be used after a suspicion of PE has been raised through clinical assessment of the patient. Moreover, they are not intended to be used as stand-alone tests and are only useful within established diagnostic strategies applied to patients in whom PE is suspected. Table 1 summarizes the validated versions of the Wells and Geneva prediction rules for PE.
D-dimer measurement
Plasma D-dimer, a degradation product of cross-linked fibrin, has been extensively investigated in VTE diagnosis [23] . D-dimer levels rise in patients with an acutely formed clot. Therefore, normal D-dimer level renders acute VTE unlikely. There are numerous available assays with different characteristics [23] . As D-dimers are used as an exclusion test, the sensitivity of the test used in a patient is a crucial issue. The quantitative ELISA or ELISA-derived assays have the highest sensitivity (over 95%) and a specificity around 40% [23, 24] . In the emergency department, a negative D-dimer ELISA can exclude PE without further testing in combination with a nonhigh or an unlikely clinical probability. A systematic review of outcome studies using the VIDAS Ò D-dimer assay to exclude PE showed a three-month thromboembolic risk well below 1% in patients left untreated after a negative test result [25] . Therefore, clinical probability and D-dimer are used in most diagnostic strategies as a first filter to avoid thoracic imaging. It allows safe exclusion of PE in approximately 1 out of 3 outpatients with suspected PE without any further testing [11, 12, [26] [27] [28] .
As the specificity of positive D-dimer for VTE is poor, this variable is not useful for confirming PE. Another important message is that a positive D-dimer test should not be considered as a reason to raise the suspicion of PE and begin a diagnostic workup. Physicians are sometimes frustrated when a D-dimer test comes back positive and feel obliged to recommend a thoracic imaging test. It is important to remember that D-dimer measurement should be performed only after a clinical suspicion of PE is raised, and in patients in whom thoracic imaging would otherwise be performed [29] . A positive Ddimer test in a patient without a prior suspicion of PE is not a clinically relevant finding. Therefore, D-dimer test should not be performed as a triage test before a medical assessment.
How to increase diagnostic usefulness of the D-dimer test? Positive D-dimer is not specific, as D-dimer levels increase in a wide variety of conditions, such as cancer, inflammation, infection, chronic kidney failure, pregnancy, previous VTE, and advancing age [30] [31] [32] . As a result, the clinical usefulness of the test in elderly patients, that is the proportion of the patients with a negative DDimer (i.e., below the predetermined cutoff, < 500 lg L
À1
for most available commercial assays) in whom PE may be ruled out is reduced [33] . Recently, the value of a progressive D-dimer cutoff adjusted to age was derived and retrospectively validated in a sample of 1712 patients [33] . The optimal age-adjusted cutoff was defined as patient's age multiplied by 10 in patients aged 50 years or more with the usual 500 lg L À1 cutoff value being used for patient younger than 50 years. This approach has been formally evaluated in a recent large multicenter prospective outcome study, in which all non-high or PE unlikely pretest probability patients with D-dimer levels below their age-adjusted cutoff were left untreated without further diagnostic testing, confirmed the safety of using the age-adjusted cutoff [34] . The D-dimer tests used in this study were highly sensitive assays (ELISA or immunoturbidimetric). Among 3346 included patients, 817 (28%) had a D-dimer level below the conventional 500 lg L À1 cutoff, and an additional 337 (12%) had a D-dimer above 500 lg L À1 but below their age-adjusted cutoff. The three-month thromboembolic risk after excluding PE based on a negative D-dimer was low and similar in both groups 1/817 (0.1%, 95% CI 0.0-0.7%) and 1/331 (0.3%, 95% CI 0.1-1.7%). The increase in the diagnostic yield of D-dimer was more pronounced in patients ≥ 75 years of age: Using the age-adjusted cutoff resulted in a five-fold increase in the proportion of patients in whom PE could be safely ruled as compared with the conventional cutoff, from 6% to 30% [34] . This means the number of patients one needs to test to obtain one negative test is 3, meaning that PE can be ruled out by negative D-dimers in one of three patients even in the elderly by the use of ageadjusted cutoff. Due to this major increase in the diagnostic usefulness of D-dimer, the age-adjusted D-dimer cutoff has been implemented in diagnostic algorithms in many ER around the world and also as part of the American College of Physicians Best Practice Advice for the evaluation of patients with suspected acute PE [35] . Other approaches to increase the yield of the D-dimer test are being developed, using a higher cutoff value in patients with a low pretest clinical probability (NCT02483442), or using cutoff values adjusted on pregnancy trimester [36, 37] .
Computed tomography pulmonary angiography (CTPA)
CTPA was introduced in the early 1990s. It allows direct visualization of pulmonary arteries after intravenous injection of iodinated contrast medium. The value of CTPA for decision making in suspected PE has evolved with improvements in technology. The older single-detector CTPA had a high specificity but a low sensitivity (around 70%) for PE [38, 39] , precluding its use as a standalone test to rule out PE. Additional lower limb venous compression ultrasound (CUS) was required, and 10-15% of patients had a proximal DVT despite a negative single-detector CTPA. Using a strategy that included CUS and single-detector, CTPA proved safe in excluding PE in two large-scale outcome studies [27, 40] . Since the introduction of higher resolution multidetector-row computed tomography (MDCT), CTPA has become the method of choice when imaging is needed for suspected [18] Simplified version [78] Age
Wells score
Original version [19] Simplified version [79] Previous PE or DVT PE [41] . It allows a direct visualization of the pulmonary arteries down to at least the segmental level [42] . Many recent prospective outcome studies provide evidence that it is safe to rule out PE after a negative CTPA [11, 12, 28, 43] . An example of a validated diagnostic algorithm for PE is displayed in Fig. 1 . Whether patients with a negative CTPA and a high clinical probability should be further investigated by venous CUS and/or ventilation-perfusion scintigraphy or pulmonary angiography is still controversial [12, 44, 45] . Another controversial area is the clinical significance of isolated subsegmental PE, that is the presence of a single subsegmental intraluminal defect on MDCT, which is found in 1-5% in patients with suspected PE. Indeed, the positive predictive value of such findings is low, and limited data suggest that such patients left untreated by anticoagulants may have an uneventful course [46] . Recent ACCP guidelines suggest that some patients with isolated subsegmental PE without associated DVT might not require anticoagulant treatment. An international prospective cohort study will provide further data on the safety of this approach (NCT01455818).
Ventilation-perfusion lung scintigraphy (V/Q scan)
Ventilation-perfusion lung scintigraphy is a non-invasive technique allowing an indirect diagnosis of PE, a so-called mismatched defect (perfusion defect with normal ventilation) usually representing PE. The interpretation of V/Q scan has long been based on criteria validated in the landmark Prospective Investigation On Pulmonary Embolism Diagnosis (PIOPED) study [17] , and their subsequent revision [47] . More recently, it has been greatly simplified and V/Q scan results are now classified into three categories: normal, high probability and non-diagnostic [43] . The high negative predictive value of a normal V/Q scan has been confirmed by several studies, including a large outcome study [43] and is recognized as a valid criterion for excluding PE. The positive predictive value of a high probability V/Q scan is approximately 90% [17] and most clinicians consider such a result enough to rule in PE. The main weaknesses of V/Q scan is the high proportion of non-diagnostic results (around 50% in recent series) and the inability to provide alternative diagnosis, as opposed to CTPA [43] . However, diagnostic strategies based on V/ Q scan have been prospectively validated in many outcome studies and were associated with a very low threemonth thromboembolic risk. Also, a randomized trial comparing V/Q scan and CTPA, suggested that both tests were associated with similar safety [43] . Overall, V/Q scan has been widely replaced by CTPA and is mainly used in patients with a contra-indication to CTPA, most often patients with renal failure. It is also important to point out that V/Q scan is the initial diagnostic test of choice to exclude chronic thromboembolic pulmonary hypertension (CTEPH) in a patient with persisting symptoms and a suspicious heart ultrasound after an initial PE.
Compression ultrasonography
CUS of lower limb veins is the main diagnostic tool for DVT. It may be used in patients with suspected PE. Indeed, the presence of a proximal DVT is highly predictive of PE, allowing to rule for the diagnosis of PE without further thoracic imaging [48] : A recent systematic review of the performances of CUS for diagnosing PE reported a sensitivity of 41% (95% confidence interval [CI], 36-46%) and a specificity of 96% (95% CI, 94-98%) [49] .
CUS was highly used in diagnostic algorithms based on single-detector CTPA. Thanks to the improved accuracy of multidetector CT, it is no longer necessary to ensure absence of DVT in patient with a negative CTPA [11] . However, it might have some interest in patients in whom CTPA is contra-indicated or not desirable, as in patients with renal failure, allergy to iodine contrast media or pregnant women. However, even if a positive CUS allows confirmation of PE diagnosis, and thus, the need for anticoagulation, the risk stratification of PE with clinical scores, echo, and/or biomarkers is still necessary.
An unfortunately often-encountered reasoning mistake is to stop further investigation after a normal CUS. This is of course not acceptable as the absence of proximal DVT does not exclude PE, and further thoracic imaging is necessary in this setting, unless an alternative diagnosis has become obvious or PE is no longer suspected. 2 In case of negative CTPA in high clinical probability patients , is used , a negative test result rules out PE only in patients with low (or unlikely) clinical probability additional imaging , e.g. lung ventilation/perfusion scintigraphy or pulmonary angiography (suspected PE) might be considered Fig. 1 . Diagnostic strategy of venous thromboembolic disease (adapted from references [80] and [34] ).
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Other imaging tests for PE
Other imaging tests are being developed to overcome some limitations of the previously described diagnostic tools.
Magnetic resonance angiography (MRA) The accuracy of gadolinium-enhanced MRA was compared to a composite reference standard (D-dimer, V/Q scan, CTPA) in the PIOPED III trial [50] . In that study, MRA was technically inadequate in a large proportion (25%) of patients. Among technically adequate tests, sensitivity was 78% and specificity 99% [50] . Similar results were found in a prospective study including 300 patients referred for CTPA in whom MRA was also performed [51] . Once again, 30% of MRA results were inconclusive. For patients with conclusive MRA results, sensitivity and specificity were around 85% and 97%, respectively, compared to the standard diagnostic workup including CTPA [51] . A recent systematic review and patient-based metaanalysis reported similar results with an overall sensitivity of 75% (95% CI 70-79%) and an overall specificity of 80% (95% CI 77-83%) [52] . Despite the fact that use of MRA could overcome some of the inconveniences of CTPA, especially the exposure to radiation and iodine contrast media, the abovementioned data on the high proportion of inconclusive results and lack of sensitivity obviously preclude the use of MRA as a routine test to rule out PE in everyday clinical practise. Moreover, MRA is not as widely available as CTPA and acquisition times are much longer. An ongoing study is assessing whether the combination of leg vein CUS and MRA would increase the diagnostic performances of MRA in suspected PE (NCT02059551).
Ventilation/perfusion single photon emission tomography (V/Q SPECT) Along with the dramatic progress in CT technology, important advances have taken place in nuclear medicine imaging over the twenty-five years that have passed since the PIOPED study was conducted with planar V/Q scans. As its name indicates, V/Q SPECT provides tomographic (transverse, coronal, and sagittal) rather than planar images. It is performed with patient in the supine position. After the ventilation study with inhalation nowadays most often of 25-30 MBq of Technegas, 100-120 MBq of radiolabeled macro-aggregated albumin (99mTc-MAA) is given intravenously for perfusion imaging. Total acquisition time is around 20 min [53] . Three-dimensional imaging allows better contrast resolution and limits the overlapping of small perfusion defects by normal tissue. These advantages should render V/Q SPECT superior to planar V/Q for the diagnosis of PE.
In a systematic review and meta-analysis recently published, the authors performed a summary receiver operating characteristics (SROC) analysis, a statistical technique applied to meta-analysis of imaging tests in order to overcome the limitations of simple pooling of sensitivities and specificities. In that study, the area under the SROC curve for V/Q SPECT was 0.99 (95% CI 0.96-1.00) as compared to 0.85 (95% CI 0.75-0.95) for planar V/Q and 0.98 (95% CI 0.94-1.00) for CTPA [54] . The patient population consisted of 2435, 3028, and 1904 patients for each of the imaging modalities, respectively. The conclusion of this analysis in terms of performance of V/Q SPECT was that V/Q SPECT is as accurate as CTPA and that both these modalities are more accurate than planar V/Q [54] .
Just as radiology societies recommend CTPA as the imaging test of choice in the diagnosis of PE, the European Association of Nuclear Medicine broadly recommends V/Q SPECT over CTPA wherever available [55] . Nevertheless, robust clinical evidence of the clear superiority of SPECT remains scarce. Moreover, before the V/ Q SPECT could be used in everyday clinical practise, a management study in which clinical decisions would be made on the basis of this test needs to be conducted. If the safety of such a strategy is confirmed in a prospective outcome study, V/Q SPECT could become a very interesting alternative to CTPA, especially in patients in whom radiation is particularly a concern (young female patients, or in patients with contra-indication to CTPA as renal failure or allergy to iodine contrast media).
CT venography When using CTPA, it is possible to also image the deep veins of the legs during the same acquisition [56] . However, this approach has not been widely implemented given that CTPA alone is able to safely rule out PE and that the added value is likely very limited [11] . Moreover, use of CT venography is associated with increased irradiation doses [57, 58] .
Unresolved issues in VTE
Patients with prior VTE Patients with prior VTE often have persistently elevated D-dimer levels. As a result, in case of suspected recurrent VTE, a lower proportion of them will benefit from noninvasive testing: The proportion of patients in whom PE was ruled out on the basis of a negative D-dimer was 16% and 33% in patients with and without a history of previous VTE, respectively [59] . Patients with prior VTE have modified symptoms and signs because of residual manifestations of previous episodes (chronic leg pain and swelling after DVT, persistent shortness of breath after PE) [60, 61] . Finally, the interpretation of imaging tests is difficult because of the frequent presence of residual thrombi that are sometimes difficult to distinguish from an acute recurrent thrombus, thereby resulting in overdiagnosis [62] . A small study, including patients with a first unprovoked VTE, suggested that baseline imaging at completion of anticoagulant therapy helped in interpreting diagnostic tests performed in cases of suspected recurrent VTE [63] . Some diagnostic criteria for recurrent PE have been proposed based on the comparison of imaging result with previous imaging. However, this strategy requires the completion of a complete baseline imaging and is only useful if (i) standardized measurements are reported, (ii) these images are available at the time and place of the suspected recurrent event, and (iii) if we dismiss possible interim asymptomatic events.
Isolated symptomatic subsegmental PE Attention to subsegmental pulmonary embolism (SSPE) has increased with the ability of CTPA to detect such small PE, not to mention ongoing debate on unsuspected PE, which will not be discussed herein. The exact incidence of SSPE in patients with suspected PE varies between 0.4 and 18% according to the literature [64] . The incidence is probably dependent on the number of A D-dimer level below the usual cut-off of 500 ng/ml should allow to rule out PE in pregnant 3 Although the rate of positive finding is lower in patients without leg symptoms, the presence of 4 While Q scan is the most often used imaging test to rule out PE in pregnant women, formal score or the Geneva rule has been validated in pregnant women.
women, even if this has never been formally validated in a prospective management outcome study a proximal DVT in a patient with suspected PE allows to rule in PE diagnosis and avoids the need for a radiating test.
validation is poor. Data regarding ventilation perfusion lung scan are also scarce. CTPA is increasingly used but is associated with the concerns of maternal radiation.
Please note that this proposed strategy has not been validated. detectors. A systematic review of diagnostic studies in patients with suspected PE found isolated SSPE in 4.7% of patients with PE diagnosed by single-detector CT and in 9.4% of patients with PE diagnosed by multidetector CTPA [65] . One of the main problems is that the reading of modern multirow CTPA is complicated and time-consuming. Radiologists are often faced with small images from which interpretation remains difficult. Of note, in the PIOPED II trial, the positive predictive value of CTPA (when compared to a composite standard reference) was of 98% for central PE but was only of 25% for SSPE [56] . Therefore, the most puzzling question might well be the following: Is this image truly a SSPE?
In a time-trend analysis of the incidence and mortality of PE in the United States, authors concluded that the introduction of CTPA was associated with changes consistent with overdiagnosis: rising incidence but minimal change in mortality and lower case fatality [3] . Even when images with thin-collimation multidetector CT are compelling, the clinical relevance and management of patients with symptomatic SSPE is controversial [66, 67] . In a recent systematic review and meta-analysis, the 3-month thromboembolic risk in patients with suspected PE who were left untreated based on a diagnostic algorithm including a negative single-detector CTPA was 0.9% (95% CI: 0.4-1.4). It was of 1.1% (95% CI: 0.7-1.4) in patients left untreated after a multidetector CTPA. Thus, the use of multidetector CT increases the rate of SSPE detection, but without resulting in a decreased 3-month thromboembolic risk [65] , suggesting that these additional SSPE may not be clinically relevant. However, only a few investigations have evaluated the outcome of untreated patients with symptomatic isolated subsegmental PE. A recent review of the literature including four diagnostic studies reported a favorable outcome in 60 patients left untreated after the diagnosis of SSPE without associated DVT [68] .
In a statement from the Fleischner Society on the management of suspected acute PE, it is suggested that the clinical relevance of small peripheral PE and the need to give anticoagulant treatment in such patients is a matter of debate [69] . They also suggested that in patients with small PE and no DVT, the risks associated with anticoagulant treatment might outweigh the benefits. More recently, the last release of the ACCP guidelines suggested that some patients with SSPE and no proximal DVT could be left untreated [70] . An ongoing study, in which patients with symptomatic SSPE are left untreated, will add useful data to this complicated topic (NCT01455818).
Pregnant women
The risk of PE is significantly increased during pregnancy, and venous thromboembolic disease remains one of the main causes of maternal mortality in developed countries.
The diagnosis of venous thromboembolic disease remains a challenge in pregnant women: Symptoms such as shortness of breath or leg swelling are common during normal pregnancy and the symptoms and signs of venous thromboembolic disease are modified during pregnancy.
D-dimer levels increase during pregnancy, reducing the likelihood of a negative result. Chan et al. proposed adapted D-dimer thresholds for many D-dimer tests [71] . However, there are no data arising from a prospective outcome study to support the safety of excluding VTE in pregnant women using these cutoffs. Moreover, no rule for assessing the pretest clinical probability has been validated. As a result, most women with suspected PE undergo imaging tests, which turns out to be negative much more frequently than in non-pregnant patients [72, 73] .
In pregnant women with suspected PE, there is a debate in the choice of the imaging thoracic test, mainly around the risk associated with fetus and mother irradiation. Some studies suggested that the level of radiation to the fetus is lower with CTPA than with V/Q scan [74] . On the other hand, some studies warned on a likely increase in the risk of breast cancer in women exposed to CTPA [75] , which could be even higher during pregnancy, and on the higher rate of inconclusive CTPA in pregnant women [76] .
In any case, these risks are clearly outweighed by the risks of PE misdiagnosis. Indeed, in terms of radiation exposure, all radiological tests fall well below the limit considered as dangerous for the fetus [9] . The key message is that all pregnant women with suspected PE should undergo a complete diagnostic workup [9, 77] . A diagnostic algorithm is proposed in Fig. 2 . However, formal prospective validation of a diagnostic strategy for PE in pregnant women is still lacking.
Conclusion
During the last two decades, the improvement in diagnostic strategies almost completely eliminated the need for invasive diagnostic testing (i.e., pulmonary angiography). Current algorithms are based on the sequential use of pretest probability assessment, D-dimer measurement, and if required chest imaging test. These strategies are fairly simple, easy to use, and cost-effective. Despite these diagnostic strategies have been very well validated, some efforts still should be done to increase their use and implementation in everyday clinical practise. Initiatives such as Choosing Wisely campaign, which for example suggest not to perform imaging in case of negative D-dimer test and a nonhigh or unlikely clinical probability, could also reduce the gap between knowledge and practise.
The diagnosis of VTE in special patient populations such as pregnant women and such as suspected VTE recurrence remains challenging. There are also some additional challenges raising that might require adjustments to current diagnostic strategies such as the reduced clinical suspicion threshold resulting in a lower proportion of VTE in suspected patients, as well as the issue of overdiagnosis and overtreatment especially regarding subsegmental PE. A better risk stratification or the use of new diagnostic modalities might help resolving some of these issues.
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